266 related articles for article (PubMed ID: 26759370)
1. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Crowley MP; Kevane B; O'Shea SI; Quinn S; Egan K; Gilligan OM; Ní Áinle F
Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
[TBL] [Abstract][Full Text] [Related]
2. Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C.
Ghansah H; Debreceni IB; Váróczy L; Rejtő L; Lóczi L; Bagoly Z; Kappelmayer J
Thromb Res; 2023 Mar; 223():44-52. PubMed ID: 36708689
[TBL] [Abstract][Full Text] [Related]
3. Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Tiong IS; Rodgers SE; Lee CH; McRae SJ
Leuk Lymphoma; 2017 Apr; 58(4):941-949. PubMed ID: 27931131
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Zangari M; Berno T; Zhan F; Boucher KM; Tricot G; Fink L
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
[TBL] [Abstract][Full Text] [Related]
5. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Kristinsson SY; Björkholm M; Schulman S; Landgren O
Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
[TBL] [Abstract][Full Text] [Related]
6. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Pedersen S
Thromb Res; 2021 Jun; 202():108-118. PubMed ID: 33819778
[TBL] [Abstract][Full Text] [Related]
7. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
[TBL] [Abstract][Full Text] [Related]
8. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance.
O'Sullivan LR; Meade-Murphy G; Gilligan OM; Mykytiv V; Young PW; Cahill MR
Br J Haematol; 2021 Jan; 192(2):322-332. PubMed ID: 32478420
[TBL] [Abstract][Full Text] [Related]
9. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
10. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.
Crowley MP; Quinn S; Coleman E; Eustace JA; Gilligan OM; O'Shea SI
J Thromb Thrombolysis; 2015 Feb; 39(2):245-9. PubMed ID: 25271000
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
12. The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
Baccouche H; Hadhri M; Aissi W; Chakroun A; Bahri D; Mahjoub S; Ben Romdhane N
Int J Lab Hematol; 2019 Oct; 41(5):684-690. PubMed ID: 31421013
[TBL] [Abstract][Full Text] [Related]
13. Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.
Goebel TE; Schiltz NK; Woodside KJ; Pillai AC; Caimi PF; Lazarus HM; Koroukian SM; Campagnaro EL
Clin Transplant; 2015 Sep; 29(9):851-7. PubMed ID: 26194021
[TBL] [Abstract][Full Text] [Related]
14. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
15. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
16. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
17. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
19. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
20. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
